Karla Kohan-Ivani et al. reported that androgens may induce a direct decrease in the levels of p21 protein, driving proliferation in epithelial ovarian cancer [67]; meanwhile, Pietri et al. present a rationale for using AR antagonists for AR-targeting treatment as a new therapy for triple-negative breast cancer, where AR signaling drives tumor progression [68,69]. This evidence concerns the gene AR and neoplasm.